drugset / Trial / NCT00158483

Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212)

NCT00158483 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

Herpes virus type 2 (HSV-2) infection - as a cofactor of human immunodeficiency virus (HIV) transmission - can be targeted by anti-herpetic specific drugs, either as a continuous prophylactic treatment during its asymptomatic shedding phase, or as an episodic treatment during clinically-apparent genital ulcerations. The main objective of this trial will be to demonstrate that acyclovir treatment given during clinical episodes (primary infection or recurrences) can reduce genital shedding of HIV, thereby contributing to a reduction of HIV infectiousness of dually infected individuals (HIV+/HSV+).

Timeline

Start
2003-05
Primary completion
—
Completion
2005-10

Outcome

Missed primary endpoint

paper CONCLUSION: Episodic therapy for herpes reduced the quantity of cervicovaginal HSV-2 DNA and slightly improved ulcer healing, but it did not decrease genital and plasma HIV-1 RNA loads. PMID 19530940 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Acyclovir Small molecule 400 mg —